/

Finch Therapeutics Group, Inc.

FNCH US

FNCH USFinch Therapeutics Group, Inc.

United States Composite

1.92

USD

-0.18

(-8.57%)

-62.60EPS Dil.

-0.03P/E

3.08MMarket Cap

Held by Insiders

53.48%

Held by Institutions

15.03%

Short % of Float

0.15%

YTD Yield

-77.25%

3Y Yield

-99.41%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

-94.74%

Net Income, GAAP

-NaN%

-98.28%

Free Cash Flow

-NaN%

7.23%

Total Cash Common Dividend

- -

Total Equity

-NaN%

-52.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-29.87

-9.61

-6.29

-12.01

-44.50

2022

-15.51

-14.31

-25.37

-16.91

-72.10

2023

-39.89

-4.33

-1.51

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

Full Time Employees: 18
Sector: Healthcare
Industry: Biotechnology
Address: 200 Inner Belt Road Somerville MA United States 02143
IPO Date: Mar 19, 2021
Website: www.finchtherapeutics.com
Business: Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Company Description

Full Time Employees: 18
Sector: Healthcare
Industry: Biotechnology
Address: 200 Inner Belt Road Somerville MA United States 02143
IPO Date: Mar 19, 2021
Website: www.finchtherapeutics.com
Business: Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.